الفهرس Only 14 pages are availabe for public view
 |  | from | 212 |  |  |
| | | from | 212 | | |
Abstract
Background: Mature B cell lymphoma accounts for more than half of the NHLs occurring in children and adolescents. Outcome has improved dramatically over the past decade. Purpose: to analyze the outcome results, Overall Survival (OS) and Event Free Survival (EFS) of patients with mature B-cell Non-Hodgkin Lymphoma receiving FAB/LMB 96 protocol, the treatment related toxicity and the impact of dose density on the outcome. Results: The mean age of the patients was 6.5 years; the distribution of primary site was abdomen 68.8%, head and neck 11.4%, mediastinum 8.1 % , bone marrow involvement 4.9% & CNS involvement 4.9%. According to the histological classification, 83.6% were BL, 11.5 % DLBCL and 4.9% matures B cell (L3) leukemia. According to FAB risk group, 4.9 % were group A, 85.2% group B and 9.8 % group C. OS & EFS for the whole group was 88.1% for both with a median follow up period of 35 months. The EFS for group A was 100 %, group B 91.5% and group C 66.7%. Conclusion: the outcome of children with mature B cell NHL treated with FAB/LMB 96 protocol in NCI {u2013}Egypt was comparable to the international results. The reduction of treatment of group B patients improved the EFS and decreased the rate of toxic morbidities and mortalities